Master dataINID | Criterion | Field | Content |
---|
| Type of IP right | SART | Patent |
| Status | ST | Pending/in force |
21 | DE file number | DAKZ | 60 2009 018 299.4 |
96 | EP file number | EAKZ | 11 00 9919.9 |
97 | EP publication number | EPN | 2431741 |
54 | Designation/title | TI | Verfahren zur Bestimmung aktiver Inhaltsstoffe in Arzneimittelvorstufen-Peg-Protein-Konjugaten mit freisetzbaren Peg-Reagentien (in-vitro-Depegylierung) |
51 | IPC main class | ICM (ICMV) | G01N 33/542 (2006.01) |
51 | IPC secondary class(es) | ICS (ICSV) | G01N 33/58 (2006.01), G01N 33/68 (2006.01), G01N 33/86 (2006.01) |
22 | DE application date | DAT | Oct 20, 2009 |
96 | EP application date | EAT | Oct 20, 2009 |
43 | Date of first publication | OT | Mar 21, 2012 |
| Date of publication of grant | PET | Aug 21, 2013 |
71/73 | Applicant/owner | INH | Nektar Therapeutics, San Francisco, Calif., US; Takeda Pharmaceutical Company Limited, Osaka-shi, JP |
72 | Inventor | IN | Culbertson, Sean M., Gurley AL 35758, US; Weber, Alfred, 1210 Vienna, AT; Anderle, Heinz, 3400 Klosterneuburg, AT; Zappe, Harold, Harvest 35749, US; Turecek, Peter, 3400 Klosterneuburg, AT; Rottensteiner, Hanspeter, 1020 Vienna, AT; Bossard, Mary J., Madison AL 35758, US; Varadi, Katalin, 1230 Vienna, AT; Zhang, Ping, Millbrae CA 94030, US; Fang, Zhihao, MadisonAL 35758, US; Schrenk, Gerald, 1220 Vienna, AT |
74 | Representative | VTR | Bird & Bird LLP, 80333 München, DE |
| Address for service | | Bird & Bird LLP, 80333 München, DE |
33 31 32
| Foreign priority | PRC PRNA PRDA
| US 10725708 P Oct 21, 2008
|
33 31 32
| Foreign priority | PRC PRNA PRDA
| US 24263409 P Sep 15, 2009
|
| Due date | FT FG | Oct 31, 2025 Annual fee for the 17th year
Patent fees |
| Patent division in charge | | 44 |
97 | EP language of publication | ELANG | EN - Englisch |
84 | Designated EP contracting states | EDS | AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, SE, SI, SK, SM, TR |
| Published EP/WO documents | EPWOPN | Original document:
EP000002431741 Searchable text:
EP000002431741 Original document:
EP000002431741B1 Searchable text:
EP000002431741B1 |
43 | Date of first publication | EVT | Mar 21, 2012 |
| Date of the first transfer into DPMAregister | EREGT | May 3, 2012 |
| Date of the (most recent) update in DPMAregister | REGT | Sep 27, 2024 (Show all update days)(Hide all update days)- Sep 27, 2024
- Sep 28, 2023; Sep 29, 2022; Nov 11, 2021; Nov 4, 2021; Sep 30, 2021; Sep 22, 2020; Sep 26, 2019; Sep 25, 2018; Oct 26, 2017; Sep 27, 2017; Sep 15, 2017; Aug 31, 2017; Jul 25, 2017; Nov 8, 2016; Nov 10, 2015; Oct 27, 2015; Nov 19, 2014; Sep 4, 2014; Jul 31, 2014; Feb 20, 2014; Nov 16, 2013; Nov 7, 2013; Oct 17, 2013; Sep 4, 2013; Sep 3, 2013; Aug 31, 2013; Aug 23, 2013; Aug 22, 2013; Feb 16, 2013
- Historical data not available for this/these date(s)
- May 3, 2012
- Date of the first transfer into DPMAregister
|
View procedures New applicant/owner details (No.: 6)INID | Criterion | Field | Content
Close details
|
---|
| Type of procedure | VART | New applicant/owner details |
| Legal/procedural status | VST | New applicant/owner details |
| Date of legal/procedural status | VSTT | Jul 24, 2017 |
| Issue number | HN | 35 |
| Year | PJ | 2017 |
| Publication date | VT | Aug 31, 2017 |
| Type of publication | PART | Bibliographic data |
| Part | HT | Part 3 |
71/73 | Applicant/owner | INH | Baxalta GmbH, Glattpark, Opfikon, CH; Baxalta Inc., Bannockburn, Ill., US; Nektar Therapeutics, San Francisco, Calif., US |
71/73 | Previous applicant/owner | INHF | Baxter Healthcare SA, Glattpark, Opfikon, CH, Baxter International Inc., Deerfield, Ill., US, Nektar Therapeutics, San Francisco, Calif., US |
View procedures New applicant/owner details (No.: 7)INID | Criterion | Field | Content
Close details
|
---|
| Type of procedure | VART | New applicant/owner details |
| Legal/procedural status | VST | New applicant/owner details |
| Date of legal/procedural status | VSTT | Sep 14, 2017 |
| Issue number | HN | 43 |
| Year | PJ | 2017 |
| Publication date | VT | Oct 26, 2017 |
| Type of publication | PART | Bibliographic data |
| Part | HT | Part 3 |
71/73 | Applicant/owner | INH | Baxalta GmbH, Glattpark, Opfikon, CH; Baxalta Incorporated, Bannockburn, Ill., US; Nektar Therapeutics, San Francisco, Calif., US |
71/73 | Previous applicant/owner | INHF | Baxalta GmbH, Glattpark, Opfikon, CH, Baxalta Inc., Bannockburn, Ill., US, Nektar Therapeutics, San Francisco, Calif., US |
View procedures New applicant/owner details (No.: 8)INID | Criterion | Field | Content
Close details
|
---|
| Type of procedure | VART | New applicant/owner details |
| Legal/procedural status | VST | New applicant/owner details |
| Date of legal/procedural status | VSTT | Nov 3, 2021 |
| Issue number | HN | 49 |
| Year | PJ | 2021 |
| Publication date | VT | Dec 9, 2021 |
| Type of publication | PART | Bibliographic data |
| Part | HT | Part 3 |
71/73 | Applicant/owner | INH | Nektar Therapeutics, San Francisco, Calif., US; Takeda Pharmaceutical Company Limited, Osaka-shi, JP |
71/73 | Previous applicant/owner | INHF | Baxalta GmbH, Glattpark, Opfikon, CH, Baxalta Incorporated, Bannockburn, Ill., US, Nektar Therapeutics, San Francisco, Calif., US |
| Date of update of the procedure | REGT | Nov 11, 2021 |